Completed PHASE4 INTERVENTIONAL 1-arm NCT01481142

Adacolumn in Refractory UC Patients Trial (ART)

Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies

Sponsor: Otsuka Pharmaceutical Europe Ltd

Conditions Ulcerative Colitis, Active Moderate

Interventions (GMA) Adsorptive Apheresis

Updated 6 times since 2017 Last updated: Oct 16, 2015 Started: Oct 31, 2011 Primary completion: May 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Ulcerative Colitis, Active Moderate and is currently completed. Otsuka Pharmaceutical Europe Ltd leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Europe Ltd

Data source: Otsuka Pharmaceutical Europe Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Grenoble, France